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Neutrophils are key innate immune effector cells that are essential to fighting bacterial and fungal pathogens. Here we report that mice carrying a hematopoietic lineage-specific deletion of Jagn1 (encoding Jagunal homolog 1) cannot mount an efficient neutrophil-dependent immune response to the human fungal pathogen Candida albicans. Global glycobiome analysis identified marked alterations in the glycosylation of proteins involved in cell adhesion and cytotoxicity in Jagn1-deficient neutrophils. Functional analysis confirmed marked defects in neutrophil migration in response to Candida albicans infection and impaired formation of cytotoxic granules, as well as defective myeloperoxidase release and killing of Candida albicans. Treatment with granulocyte/macrophage colony-stimulating factor (GM-CSF) protected mutant mice from increased weight loss and accelerated mortality after Candida albicans challenge. Notably, GM-CSF also restored the defective fungicidal activity of bone marrow cells from humans with JAGN1 mutations. These data directly identify Jagn1 (JAGN1 in humans) as a new regulator of neutrophil function in microbial pathogenesis and uncover a potential treatment option for humans.
Neutrophils constitute a central arm of the innate immune responses against a variety of pathogens relevant in human infectious diseases 1, 2 . An impairment of either the development or function of these cells has severe pathological consequences, characterized by recurrent and often chronic infections due to a failure of the immune system to combat and clear pathogens 3 . In our accompanying paper 4 , we report that people suffering from severe congenital neutropenia carry mutations in JAGN1 (encoding Jagunal homolog 1). To test whether Jagn1 is the causal gene responsible for impaired neutrophil function in mice, we generated Jagn1-mutant mice.
Jagn1 is an endoplasmic reticulum (ER)-resident transmembrane protein encoded by the Jagn1 gene situated on mouse chromosome 6. We first attempted to generate mice with complete knockout of Jagn1 but never obtained viable Jagn1-null offspring, owing to lethality around embryonic day 8.5 for as-yet-unknown reasons (data not shown). Consequently, we created mice carrying two loxP sites flanking exon 2 of Jagn1, which encodes the major portion of the Jagn1 protein ( Supplementary Fig. 1a) , and crossed these mice to a Vav1-iCre transgenic line that drives Cre expression in all hematopoietic cells 5 . To verify deletion of Jagn1, we prepared genomic DNA from the spleens and mesenteric lymph nodes (mLNs) of control mice carrying two loxP-flanked (floxed) Jagn1 alleles (hereafter termed Jagn1 fl/fl ) or two floxed alleles of Jagn1 plus the Vav1-iCre transgene to generate hematopoietic-specific Jagn1 knockout mice (termed Jagn1 ∆hem ). Fig. 1b ) and protein blot analysis (Supplementary Fig. 1c ). Cre-mediated deletion of exon 2 of Jagn1 led to a loss of Jagn1 protein expression in spleen-and mLN-derived hematopoietic cells. Moreover, whereas peripheral blood neutrophils isolated from Jagn1 fl/fl mice readily expressed detectable levels of Jagn1, cells isolated from Jagn1 ∆hem littermate mice did not show any Jagn1 staining ( Supplementary  Fig. 1d ). Thus, we have successfully ablated Jagn1 expression in hematopoietic cells.
Loss of exon 2 was verified by genomic PCR (Supplementary
Although Jagn1 was expressed in all major hematopoietic lineages tested (Supplementary Fig. 1e ), its deletion did not cause any gross abnormalities in total cellularity or the cellular composition of the mLN, spleen, thymus or bone marrow ( Supplementary  Figs. 1f-j and 2a-f) . Furthermore, Jagn1-deficient hematopoietic progenitors did not show any competitive disadvantage in reconstituting major immune cell lineages in mixed-bone marrow chimaeric mice ( Supplementary Fig. 2g-i) . Thus, blood cell-specific loss of Jagn1 in mice has no obvious effect on the development of all hematopoietic lineages analyzed and Jagn1 ∆hem mice exhibit normal numbers of neutrophils in the bone marrow, secondary lymphoid organs and blood.
In mice, neutrophils have been found to be essential in combatting infections by the human fungal pathogen Candida albicans [6] [7] [8] [9] [10] . Because humans with JAGN1 mutations develop infections that are Jagunal homolog 1 is a critical regulator of neutrophil function in fungal host defense prototypic of neutrophil defects 4 , we tested the ability of Jagn1 ∆hem mice to mount an immune response against Candida albicans. Systemic Candida albicans infection caused significantly more pronounced weight loss in mice that lacked Jagn1 (Fig. 1a) . Jagn1 ∆hem mice also succumbed significantly earlier to Candida albicans infection than their control littermates (Fig. 1b) . In line with this increased morbidity and mortality, we observed massively increased fungal burdens in all organs tested for Jagn1 ∆hem mice (Fig. 1c) . The increased fungal burden in Jagn1-deficient mice was accompanied by a switch to hyphal growth, associated with increased Candida albicans virulence and tissue destruction 11 , as assessed by periodic acid-Schiff staining (Fig. 1d) . In histological analysis, we observed severe multifocal tubulointerstitial nephritis, splenitis with expanded white pulp and diffuse inflammatory infiltrations into the liver and lungs of Candida albicans-infected Jagn1 ∆hem mice ( Fig. 1d and Supplementary Fig. 3 ). These data show that Jagn1 ∆hem mice cannot To elucidate the potential mechanism of impaired neutrophil activity, we performed mass spectrometry analysis of purified bone marrow neutrophils to assess both differences in protein expression and protein glycosylation. To this end, we applied a new technology that we recently developed to assess the abundance of N-glycosylation and map glycosylated residues directly to proteins on a proteome-wide scale. We detected specific changes in a limited set of N-glycosylations ( Supplementary Fig. 4a and Supplementary Table 1 ). In particular, we observed upregulation of triantennary Gal-α-1,3-Gal-terminated N-glycoforms and reduction in biantennary sialic acid-terminated structures in Jagn1 ∆hem neutrophils (Fig. 2a) . Our data thus indicate that loss of Jagn1 alters glycoprotein processing and/or protein trafficking within the ER and Golgi compartments.
Intriguingly, nearly all N-glycosylation changes could be mapped to proteins involved in neutrophil effector functions or the migratory capabilities of these cells. In particular, we observed alterations in the glycosylation of the cell adhesion and migration molecules CD177, CD11b (integrin αM) and CD18 (integrin β2) [12] [13] [14] [15] [16] (Fig. 2b) . Moreover, we detected marked alterations in the glycosylation of neutrophil collagenase (Mmp8), matrix metalloproteinase 9 (Mmp9), lactoferrin (Ltf), lipocalin 2 (Lcn2), haptoglobin (Hp) and neutrophilic granule protein (Ngp) (Fig. 2c) , molecules implicated in tissue remodeling and the cytotoxic effector functions of neutrophils 17 . N-glycosylation differences were equally evident in activated peritoneal neutrophils recruited upon local Candida albicans challenge ( Supplementary Fig. 4b and Supplementary Table 1) . Thus, loss of Jagn1 results in defined changes in N-glycosylation for key molecules involved in neutrophil migration and neutrophil-mediated cytotoxicity.
We next wanted to assess whether the pathways uncovered by the glycosylation changes were functionally affected in Jagn1-deficient neutrophils. We first assessed the mobilization and tissue recruitment of neutrophils. Injection of Candida albicans into the peritoneal cavity led to a rapid increase in peripheral blood neutrophil levels in comparison to no treatment, both in control and Jagn1 ∆hem mice (Fig. 3a) . In striking contrast, recruitment of neutrophils to the peritoneal cavity was significantly reduced in Jagn1 ∆hem mice (Fig. 3b) . This impaired innate immune response to intraperitoneal Candida albicans infection was also reflected by significantly decreased tumor necrosis factor (TNF)-α levels in both the serum and intraperitoneal lavage of Jagn1 ∆hem mice (Fig. 3c) . Moreover, in vitro migration assays using Boyden chambers showed a marked migratory defect for Jagn1 ∆hem neutrophils in response to the chemoattractant N-formyl-methionine-leucine-phenylalanine (fMLP) (Fig. 3d) . We also assessed neutrophil recruitment to organs 24 h after systemic infection with Candida albicans. We detected markedly decreased recruitment of Jagn1 ∆hem neutrophils to the kidney and lung (Fig. 3e) , a finding that correlated with the increased pathogen load in these organs (Fig. 1c) . Our data thus indicate that Jagn1-defective l e t t e r s neutrophils cannot effectively migrate to the site of infection following peritoneal or systemic Candida albicans challenge.
At later stages of systemic infection, we did find an accumulation of macrophages and also neutrophils in the kidneys of Jagn1 ∆hem mice (Supplementary Fig. 5 ), suggesting that, in addition to defects in initial recruitment, Jagn1 ∆hem immune cells must have functional defects in controlling Candida albicans infection. To shed light on the mechanism(s) underlying these defects, we first tested for the production of reactive oxygen species (ROS) by neutrophils, dendritic cells and monocytes/macrophages in Candida albicans co-cultures. We did not detect any difference in these cell types with respect to their ability to produce ROS (Fig. 3f) . Additionally, we assessed the ability of these cell types to kill Candida albicans using an in vitro cytotoxicity assay. Notably, only Jagn1-deficient neutrophils showed a reduction in their killing potency (Fig. 3g) In all panels except h, data are shown as means ± s.d. P values were calculated using the Student's t test, with the exception of those in i (two-way ANOVA over the entire time period) and j (log-rank test). *P < 0.05, **P < 0.01, ***P < 0.001. npg 1 0 3 2 VOLUME 46 | NUMBER 9 | SEPTEMBER 2014 Nature GeNetics l e t t e r s neutrophils was not impaired (Fig. 3h) . These data indicate that Jagn1-deficient neutrophils but not Jagn1-mutant macrophages and dendritic cells exhibit impaired killing of Candida albicans. To clear microbial pathogens, neutrophils apply a diverse arsenal of cytotoxic substances stored in preformed granules 18 . Jagn1 ∆hem blood neutrophils showed a striking reduction in granularity, as detected by flow cytometry (Fig. 4a) , resulting from a failure to acquire granularity during their differentiation in the bone marrow (Fig. 4b) . At least four types of granules and vesicles have been described in human and mouse neutrophils 17, 19 . Our glycoproteome data uncovered alterations in the glycosylation of proteins localized to primary, secondary and tertiary granules (Fig. 2c) . Electron microscopy studies of purified neutrophils directly confirmed reduced numbers of primary and secondary granules (Fig. 4c,d ). In line with the diminished numbers of primary and secondary granules, we detected markedly reduced levels of the primary granule marker myeloperoxidase (MPO) and the secondary and tertiary granule markers Mmp8 and Mmp9 in blood neutrophils ( Supplementary Fig. 6a,b) . Because MPO has been identified as, among other pathways, an important neutrophil effector molecule for Candida albicans clearance [20] [21] [22] , we tested whether reduced levels of MPO extended to impaired MPO release. Indeed, we observed a significantly decreased ability of Jagn1-deficient neutrophils to release MPO when challenged in vitro with Candida albicans (Supplementary Fig. 6c ). These data show that loss of Jagn1 in mice severely affects the maturation of neutrophil granules, which are pivotal for neutrophil effector functions.
The cytokines granulocyte colony-stimulating factor (G-CSF) and GM-CSF are central regulators of neutrophil differentiation and function, and G-CSF is routinely used to treat neutropenia [23] [24] [25] . In JAGN1-mutant humans, we observed defective G-CSF signaling in vitro, and the condition of the affected individuals did not improve after G-CSF therapy. We therefore assessed G-CSF signaling in mouse Jagn1 ∆hem neutrophils and observed reduced signal transducer and activator of transcription 3 (STAT3) phosphorylation in Jagn1-deficient mouse neutrophils upon low-dose G-CSF stimulation ( Supplementary  Fig. 6d ). Cell surface expression and total levels of the α chain of the G-CSF receptor (G-CSF-Rα) were comparable between control and Jagn1-mutant neutrophils (Supplementary Fig. 6e ). In agreement with defective G-CSF-R signaling in vitro, Jagn1 ∆hem neutrophils also showed a striking reduction in STAT3 phosphorylation after in vivo Candida albicans infections (Supplementary Fig. 6f) . In contrast to impaired G-CSF-R signaling, we observed normal Stat5 phosphorylation in response to GM-CSF stimulation (Supplementary Fig. 6g) . Cell surface expression of the GM-CSF-Rα was slightly elevated in Jagn1 ∆hem mouse neutrophils (Supplementary Fig. 6h) .
Remarkably, treatment of isolated bone marrow neutrophils with GM-CSF but not G-CSF rescued the impaired MPO release of Jagn1 ∆hem neutrophils and restored their ability to kill Candida albicans (Fig. 4e,f) . To test whether these in vitro rescue experiments could be extended to an in vivo situation, we treated Jagn1 fl/fl and Jagn1 ∆hem mice with GM-CSF. Whereas GM-CSF treatment did not affect MPO expression levels in Jagn1 fl/fl blood neutrophils, it partly restored MPO expression in Jagn1 ∆hem neutrophils (Fig. 4g) . To test for additional beneficial effects, we pretreated Jagn1 ∆hem and control Jagn1 fl/fl mice with GM-CSF and then challenged them with a systemic Candida albicans infection to assess neutrophil recruitment to organs. Treatment of Jagn1 ∆hem mice with GM-CSF led to complete rescue of the neutrophil recruitment defects at 24 h after systemic infection (Fig. 4h) . Most notably, in vivo treatment with GM-CSF completely rescued the increased weight loss as well as the reduced survival of Candida albicans-infected Jagn1 ∆hem mice to levels seen in GM-CSF-treated control Jagn1 fl/fl mice (Fig. 4i,j) . Thus, GM-CSF treatment rescues antifungal cytotoxicity in Jagn1-deficient neutrophils and protects mutant mice from accelerated mortality after Candida albicans challenge.
Because we observed rescue of the mutant mouse phenotype with GM-CSF treatment, we set out to test whether we could translate this finding into humans. We obtained bone marrow samples from subjects P12 and P13 (see ref. 4 for information on the subjects). These individuals had a reduced number of granulocytes in their bone marrow in comparison to healthy controls ( Supplementary  Fig. 6i,j) . Notably, bone marrow granulocytes isolated from JAGN1-mutant subject P12 did respond to GM-CSF treatment, as assessed by intracellular staining for phosphorylated STAT5 (Fig. 4k) . We next set up an in vitro cytotoxicity assay to test the ability of JAGN1-mutant cells to kill Candida albicans. Cells from JAGN1-mutant subjects were defective in their ability to kill Candida albicans in comparison to cells from healthy donors. Remarkably, GM-CSF treatment restored the in vitro cytotoxic activity of these cells to the levels observed in control cells (Fig. 4l) . These data suggest that GM-CSF treatment might represent an efficacious treatment option for JAGN1-mutant humans.
Our data identify Jagn1 as a critical new regulator of neutrophil migration and effector function and mirror results from JAGN1-mutant humans. Inactivation of Jagn1 (JAGN1 in humans) causes aberrant granule formation, impaired cytotoxicity against Candida albicans and defective protein glycosylation. Applying a new mass spectrometry technique allowed us to directly identify these glycosylation changes and map them to the affected proteins on a proteome-wide scale. Our data show that Jagn1 deficiency in neutrophils results in alterations in the N-glycosylation of proteins essential for cell adhesion and migration and for neutrophil-mediated cytotoxicity. Altered N-glycosylation has already been reported to critically impinge on the function of cell surface molecules such as integrins [26] [27] [28] and antifungal and antibacterial proteins [29] [30] [31] . Of note, human JAGN1-and mouse Jagn1-deficient neutrophils exhibit different alterations in glycosylation, reflecting fundamental differences in the glycosylation machinery between mice and men 32 .
Whereas humans with mutant JAGN1 exhibit reduced neutrophil numbers 4 , we did not observe neutropenia in our mutant mice; this difference might be due to the genetic background of our mice or chronic exposure to pathogens and/or might reflect species-specific differences, which need to be explored in additional experiments. Notably, in both human JAGN1-mutant and mouse Jagn1-null neutrophils, we found defective signaling via the G-CSF receptor, whereas signaling via the GM-CSF receptor was apparently normal. In vivo treatment with GM-CSF protected Jagn1-mutant mice from lethality after septic Candida albicans infections. Notably, our findings in mice translated to humans: in vitro GM-CSF treatment completely restored the defective fungicidal function of bone marrow cells from JAGN1-mutant individuals toward Candida albicans. Thus, our mouse studies have allowed us to uncover a viable treatment option for JAGN1-mutant humans that now needs to be tested in clinical trials.
URLs. UniProt, http://www.uniprot.org/.
MeTHodS
Methods and any associated references are available in the online version of the paper.
npg l e t t e r s Accession codes. All mass spectrometry glycoproteomics data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org/) via the PRIDE partner repository 33 with the data set identifiers PXD001008 and PXD001009. 
oNLINe MeTHodS
Generation of Jagn1-deficient mice. To obtain Jagn1 conditional knockout mice, targeted embryonic stem (ES) cells were obtained from Eucomm (clone HEPD0614_4_D07) and injected into day 3.5 blastocysts. After germline transmission, mice were crossed to Vav1-iCre transgenic mice 5 . Mouse genotypes were determined by PCR analysis (see Supplementary Table 2 for primer sequences). Of note, only age-and sex-matched littermates from the same breeding were used for experiments. All mice were bred and maintained in accordance with ethical animal license protocols, complying with current Austrian law.
Generation of mixed-bone marrow chimeric mice. To generate bone marrow chimeric mice, 8-week-old CD45.1 Rag1-deficient mice were irradiated (split dose, 2 × 6 Gy) and reconstituted 18 h after the second irradiation with the described mixture of donor cells (3 × 10 6 donor cells per mouse) by intravenous injection. Experiments were carried out 10 weeks after reconstitution.
Histology. For histological analysis, 2.5-µm sections of fixed and paraffinembedded tissues were stained with hematoxylin and eosin, periodic acidSchiff (counterstained with hematoxylin) or, for immunohistochemistry, specific antibodies after antigen retrieval (BOND Epitope Retrieval kit, Leica). Specimens were scanned using a Mirax slide scanner. See Supplementary Table 2 for the antibodies used in this study. To assess nuclear morphology and the MPO content of peripheral blood neutrophils, blood smears were obtained, dried for 5 min, fixed with 4% formaldehyde, stained with hematoxylin and eosin or an MPO-specific antibody (diluted 1:200), and scanned with a Mirax slide scanner. To analyze the distribution of MPO staining intensity, Definiens Tissue Studio software was applied. To train the software algorithm on differentiating neutrophils and distinguish them from other leukocytes, target objects and non-target objects were manually classified in a representative area of a slide. The definition of target objects was based on morphology and immunostaining. The optimized algorithm was then applied to analyze all slides automatically. To confirm the quality of the analysis, spot tests were performed on slides from both Jagn1 fl/fl and Jagn1 ∆hem samples.
Neutrophil isolation and differentiation of dendritic cells, monocytes and macrophages. Neutrophils were isolated from the tibias and femurs of mice using a Percoll gradient (GE Healthcare) as previously described 34 or were sorted using a FACSAria III cell sorter (BD Biosciences) after labeling with antibody to Ly6G (see Supplementary Table 2 for information on the antibodies used in this study). Purified neutrophils were cultured in RPMI-1640 medium (PAA), and recombinant G-CSF (Biolegend) or GM-CSF (eBioscience) was added to the culture medium. Dendritic cells or monocytes and macrophages were obtained by differentiation from bone marrow precursor cells as described 35 . Peripheral blood neutrophils were obtained either by submandibular or tail vein bleeding and were collected in potassium-EDTA tubes (Sarstedt). Red blood cells were lysed using ammonium chloride-potassium (ACK) buffer.
Flow cytometry and hemocytometry. Antibody labeling of leukocytes was carried out in FACS staining buffer (PBS supplemented with 2% EDTA and 2 mM EDTA) on ice for 30 min after blocking Fc receptors. See Supplementary Table 2 for a list of antibodies used in this study. Intracellular staining for the regulatory T cell marker Foxp3, cytokines and Jagn1 was carried out using the Foxp3 staining kit (eBioscience) according to the manufacturer's instructions. For cytokine detection, splenocytes were activated with phorbol 12-myristate 13-acetate (PMA) and ionomycin (100 ng/ml and 1 µg/ml, respectively) for 3 h in the presence of brefeldin A (eBioscience) before cell surface marker staining, fixation and intracellular staining. To study Stat3 and Stat5 phosphorylation in mouse neutrophils, peripheral blood neutrophils were obtained as described above and stimulated for the indicated time periods with recombinant mouse GM-CSF (eBioscience) or G-CSF (Biolegend) at the indicated concentration. To assess STAT5 phosphorylation in human granulocytes, CD34 − human bone marrow cells were serum starved for 2 h and were subsequently stimulated with recombinant human GM-CSF (50 ng/ml; eBioscience) for 15 min. Intracellular staining for phosphorylated STAT3 and phosphorylated STAT5 was carried out using the Phosflow kit (BD Biosciences) according to the manufacturer's instructions. Cells were recorded on an LSR II flow cytometer (BD Biosciences), and data were analyzed using FlowJo v10.0.6 software (Tree Star). White and red blood cell counts were obtained using a Vet ABC Hematology Analyzer (Scil).
Measurements of cytokine production, MPO release and reactive oxygen species. Concentrations of TNF-α in the peritoneal lavage and serum were analyzed with plate-bound ELISA kits according to the manufacturer's instructions (ELISA Ready-SET-Go, eBioscience). MPO concentration was measured using plate-bound ELISA kits according to the manufacturer's instructions (HK210 Mouse MPO, Hycult Biotech). Production of ROS in isolated neutrophils, bone marrow-derived dendritic cells and bone marrow-derived monocytes/macrophages was measured with an assay using luminol as the probe in real time over 120 min as described 36 .
In vivo fungal infections and GM-CSF treatment. To test for a role of GM-CSF (eBioscience) in regulating MPO expression levels in blood neutrophils, 8-to 10-week-old mice were injected intraperitoneally with 0.5 µg of recombinant GM-CSF (eBioscience) daily for 3 d and were bled 24 h after the final treatment to obtain blood neutrophils for cytological analysis. For in vivo Candida albicans challenge, 8-to 10-week-old male mice were intravenously infected with 1 × 10 5 CFU of Candida albicans strain SC5314 in PBS for 21.5 g of mouse weight. Before infection, fungi were grown in normal YPD medium (2% glucose) at 30 °C with agitation. Mice were monitored twice daily, and loss of body weight was recorded. For survival experiments, mice were monitored for up to 21 d. For GM-CSF rescue experiments, mice were treated with 0.5 µg of recombinant mouse GM-CSF in PBS or with PBS alone as a vehicle control by intraperitoneal injection. Treatment was started 24 h before infection with Candida albicans, and mice were subsequently treated with GM-CSF every 48 h. To determine fungal burden in different organs, mice were sacrificed, and the spleen, liver, kidneys and lungs were removed aseptically at necropsy, rinsed with sterile PBS, weighed and placed in 1.5 ml of sterile tissue lysis buffer (200 mM NaCl, 5 mM EDTA, 10 mM Tris, 10% glycerol, 1× protease inhibitor cocktail (Roche)) on ice. Organs were aseptically homogenized using an Ika T10 Basic Ultra-Turrax homogenizer (Ika, Staufen). Serial dilutions of homogenates were plated in triplicate on YPD plates (1% yeast extract, 1% peptone, 2% dextrose) containing ampicillin, tetracycline and chloramphenicol. Colonies were counted after 48 h of incubation at 30 °C. The fungal burden was calculated as CFU/g tissue. For neutrophil recruitment experiments, mice were injected intraperitoneally with 5 × 10 6 CFU. After 24 h, peritoneal cells were collected with ice-cold, sterile PBS, and total cell numbers and the cellular composition of the infiltrates were analyzed by flow cytometry. For organ recruitment experiments, mice were infected intravenously with 100,000 CFU/21.5 g body weight. After 24 h of Candida albicans challenge, mice were sacrificed, and organs were digested with liberase according to the manufacturer's instructions (Roche) and filtered through 70-µm mesh. An aliquot was stained with antibodies against Ly6G, CD45, GR-1 and CD11b, and cells were recorded using an LSR II flow cytometer (BD Biosciences) (see Supplementary  Table 2 for information on the antibodies used in this study).
Phagocytosis assays. Phagocytosis of Candida albicans was performed as described 35 . Briefly, Candida albicans (strain SC5314) cells were labeled with Alexa Flour 488 (Invitrogen) in 100 mM HEPES buffer (pH 7.5). Isolated neutrophils were then co-cultured with labeled Candida albicans for 45 min at 37 °C. Adherent fungal cells were quenched with trypan blue (Sigma-Aldrich), and the rate of phagocytosis was assessed by flow cytometry.
Candida albicans killing assays. For in vitro killing assays, isolated neutrophils, bone marrow-derived dendritic cells and bone marrow-derived monocytes and macrophages (all cultured in RPMI-1640) or human CD34 − bone marrow cells (cultured in Dutch-Modified RPMI-1640) were plated in replicates at a density of 1 × 10 5 cells/well in 96-well plates. Cells were incubated with Candida albicans at a multiplicity of infection of 1:500 for 24 h. After incubation, neutrophils were fixed by the addition of paraformaldehyde to a final concentration of 4%. After fixation, Candida albicans cells were stained with crystal violet (Sigma), and killing was assessed by comparing Candida albicans colonies in wells with and without neutrophils. 
